Pier Capital, LLC Anavex Life Sciences Corp. Transaction History

Pier Capital, LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 15, 2023	SELL	$7.65 - $14.43 $795,271 - $1.5 Million	-103,957 Reduced 27.02%	280,854 $2.6 Million
Q3 2022 Nov 15, 2022	BUY	$8.9 - $12.86 $5,624 - $8,127	632 Added 0.16%	384,811 $3.97 Million
Q2 2022 Aug 15, 2022	SELL	$7.31 - $12.84 $764,004 - $1.34 Million	-104,515 Reduced 21.39%	384,179 $3.85 Million
Q1 2022 May 10, 2022	BUY	$9.74 - $17.69 $2.07 Million - $3.76 Million	212,350 Added 76.84%	488,694 $6.02 Million
Q4 2021 Feb 10, 2022	BUY	$16.88 - $23.31 $2,717 - $3,752	161 Added 0.06%	276,344 $4.79 Million
Q3 2021 Nov 10, 2021	BUY	$16.82 - $25.75 $4.65 Million - $7.11 Million	276,183 New	276,183 $4.96 Million

154

27.3M

515K

838K

Ticker AVXL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,942,800
Market Cap $581M
Description
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patien...

Get notified when there are updates to the investment portfolio of Pier Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Pier Capital, LLC with notifications on news.